CJC-1295 with DAC Cycle Length: Studies, Breaks & Limits

There is no established human cycle length in the sources reviewed. A cycle usually means a planned period of use followed by a break. A study can instead give one or a few injections, then watch what happens. Those are different timelines.

This guide gives the most weight to the original human papers and the FDA review of those studies. Supplier schedules and community reports cannot fill gaps in clinical evidence.

In the discussions reviewed, people proposed 8-week and 12-week courses of CJC-1295 with DAC. These are examples of plans people shared, not proof of a safe or effective cycle. The posts also discuss other compounds, which makes it harder to judge any one product.

A September 2026 discussion in r/Biohacking describes a proposed eight-week course. In a May 2026 comment in r/PeptidePathways, a user reported four weeks elapsed and a planned twelve weeks. Neither establishes a completed, controlled comparison of those lengths.

These threads specify DAC; No DAC and ipamorelin blends cannot be treated as the same product. The human trials below used one injection or only two or three injections during 28- or 49-day studies. Those study windows do not validate the longer community plans or establish a break before another course.

Community sources reviewed October 14, 2026. This is a small sample of discussions, not a survey or evidence of community consensus.

Teichman and colleagues reported two placebo-controlled trials in healthy adults. The table uses the FDA's detailed study review to separate injections from follow-up.

The hormone pulse study used overnight sampling before treatment and one week later. It found that growth hormone still rose in pulses. It did not test months of use or compare breaks between repeat courses.

A week count is only useful when we know what it describes. A paper may track people for several weeks even though they received the compound once. It may also measure a blood marker long after the final injection. Read each number with its label attached.

For example, a follow-up visit on day 28 is a check on the participant. It does not mean treatment continued until that day or that another course should begin then.

Half-life is the time it takes for the amount of a drug in the body to fall by about half. Teichman reported an estimated half-life of 5.8–8.1 days. That helps explain the long exposure after an injection. It does not set a safe length of use or a safe restart date.

The studies measured growth hormone and IGF-1, a hormone that carries many growth hormone signals. Changes in these blood markers do not by themselves show better recovery, fat loss, or long-term health.

The Teichman trials studied healthy adults ages 21–61. Participants received CJC-1295 or a placebo, a comparison treatment without the active drug. Treatment assignments were hidden during the study. This helps separate drug effects from expectations.

The trials measured drug levels, hormone changes, and short-term safety. They did not compare eight weeks with twelve weeks, or one break length with another.

A blood marker is a measurement, such as a hormone level. A health benefit is a change in how someone feels or functions. Higher GH or IGF-1 does not by itself prove better strength, sleep, or injury recovery.

A higher hormone level does not show that longer use will help more. A return to the starting level also cannot prove that another course is safe.

The reviewed studies do not give an evidence-based answer. A gap between injections within a study is not the same as a break between full courses. Neither tells us when repeated long-term use becomes safe.

Continuous use means using a product without a planned break. Repeat courses mean stopping, then starting again. These studies did not compare the long-term benefits or harms of those approaches.

To study repeat use, researchers would need to test a stated course length, break, and number of courses, then follow people long enough to look for harms.

Tolerance means a response weakens with repeated use. The one-week hormone-pulse finding did not test whether this happens after months, or whether a break reverses it.

No. DAC is a chemical feature that helps the studied peptide attach to albumin, a protein in the blood. That changes how long it stays in the body. The FDA review treats DAC and non-DAC forms as distinct substances; their timing cannot be treated as interchangeable.

The older human studies tested the long-acting compound. They did not clearly report its salt form, a chemical detail of the product. Their results do not apply to every vial sold as CJC-1295. See the No DAC background page for that separate topic.

CJC-1295 is often discussed alongside ipamorelin or other compounds. Adding another active ingredient changes the research question. A study of CJC-1295 alone cannot tell us the best duration, break, or safety profile of a combined product. The presence of one familiar name does not make the whole blend studied.

Keep three distinctions clear when comparing pages or product labels: DAC versus No DAC, a single compound versus a blend, and the studied material versus a seller's vial. A similar product name is a starting point for checking identity, not proof that study results transfer to it.

CJC-1295 is not an FDA-approved drug. FDA's review says long-term human safety is unknown. Short trials cannot establish the safety of repeated courses over months or years.

These concerns are not solved by adding an off-period. Animal findings also cannot set a human cycle. Questions about hormone symptoms, treatment, or a reaction to a product belong with a licensed clinician.

Use this checklist when a page, post, or product listing presents a precise on-and-off schedule. It helps separate what a source actually found from the extra advice someone attached to it.

If the source cannot answer one of these questions, keep that gap visible. Precise-looking week counts can still rest on guesswork. 'Not established' is often the most useful answer because it prevents a research observation from turning into an unsupported instruction.